Comprehensive Epilepsy Program marks 100th responsive neurostimulation procedure
-
April 8, 2026
-
1 min
April 8, 2026
An investigational oral Shigella sonnei vaccine showed robust protection against shigellosis in a phase 2 controlled human infection trial.
by Teraya Smith
July 23, 2026
Annette Kim shares her experience of a real-world clinical laboratory transition to whole-genome sequencing
July 24, 2026
Application of newly proposed GRAPPA and EULAR criteria in a longitudinal cohort identified progressively smaller groups of patients with early psoriatic arthritis who experienced persistently worse patient-reported outcomes.
July 23, 2026